Pan-KRAS inhibition selectively halts proliferation of KRAS G12S HOS-143B cells.

<p>(A) Cytotoxicity of daraxonrasib in HOS-143B and HOS cells. (B) Proliferation assay across three days of treatment with DMSO or 5 nM daraxonrasib in HOS and 143B cell lines. (C-D) Colony forming assay and quantification of colony numbers of (C) HOS-143B and (D) HOS. All experiments were con...

Deskribapen osoa

Gorde:

Xehetasun bibliografikoak
Egile nagusia:	Okkeun Jung (21243431) (author)
Beste egile batzuk:	Angelene Soto (22021910) (author), Andrew L. Wolfe (18198851) (author), Shahana S. Mahajan (22021913) (author)
Argitaratua:	2025
Gaiak:	Biophysics Biochemistry Cell Biology Molecular Biology Pharmacology Biotechnology Developmental Biology Cancer Hematology Infectious Diseases Plant Biology Biological Sciences not elsewhere classified Chemical Sciences not elsewhere classified selectively inhibits osteosarcomas promote cell motility activating protein rasa1 bound kras enhanced daraxonrasib selectively suppresses daraxonrasib selectively inhibited daraxonrasib selectively attenuated recently developed pan matrix metalloproteases mmp9 kras mutant osteosarcoma kras mutant hos kras inhibitor daraxonrasib halting akt signaling type osteosarcoma cells kras mutations activated kras ras inhibitor ets1 signaling daraxonrasib suppressed hos cells 143b cells treating osteosarcoma osteosarcoma patients kras wild wide array underlying mechanism type controls small subset shows promise remain unclear promising agent migratory ability metastatic potential lung cancers increased prevalence ets1 pathway also known activity assays
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Pan-KRAS inhibition selectively halts proliferation of KRAS G12S HOS-143B cells.

Antzeko izenburuak